Do you want to read an article? Please log in or register.
Non-Cancer Causes of Death in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Analysis
Genitourinary Cancer
Related content
Genitourinary Cancer
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study
Prostate Cancer Prostatic Dis
Büttner T, Rizzo M, Bernal Vaca L, Molina-Cerrillo J, Alonso-Gordoa T, Juárez A, Buchler T, Seront E, Kucharz J, Gandur Quiroga MN, Bourlon MT, Bögemann M, Kopecky J, Rescigno P, Fiala O, Rodriguez-Vida A, Myint ZW, Ürün Y, Scagliarini S, Poprach A, Matthews D, Li H, Rizzo A, Mosca A, Lenci E, Melichar B, Wenzel M, Mandell P, Massari F, Antonarakis ES, Santoni M
doi: 10.1038/s41391-025-01067-3
Genitourinary CancerFurther Publications
Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis
Eur J Cancer
Shore N, Morgans AK, Boegemann M, Gallagher E, Paracha N, Serafini P, Pushkarna D, Pourrahmat MM, Kurt M, Abrams KR
doi: 10.1016/j.ejca.2025.115513
Genitourinary Cancer
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial
Ann Oncol
Tripathi A, Chen Y, Jarrard DF, Garcia JA, Dreicer R, Liu G, Hussain MH, Shevrin DH, Cooney MM, Eisenberger MA, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Carducci MA, DiPaola RS, Sweeney CJ
doi: 10.1016/j.annonc.2025.08.004
Genitourinary Cancer
Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study
Urol Oncol
Rinderknecht E, Bielstein G, Cathomas R, Schlack K, Bastian JLD, Darr C, Unland-Gies D, Kappler P, Paffenholz P, Richter J, Müller M, Seitz AK, Steinestel J, Heidegger I, Burger M, Breyer J, Schnabel MJ
doi: 10.1016/j.urolonc.2026.111028
Genitourinary Cancer
Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate Cancer
Adv Ther
Bilen MA, Burbage S, Rossi C, Khilfeh I, Diaz L, Wang Y, Pilon D, Brown G, Shore N, Lowentritt B, Lin DW
doi: 10.1007/s12325-025-03270-z
Genitourinary Cancer
Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Clin Cancer Res
Hage Chehade C, Graf RP, Ozay ZI, Gebrael G, Sayegh N, Li G, Maughan BL, Antonarakis ES, McKay RR, Agarwal N, Swami U
doi: 10.1158/1078-0432.CCR-25-1178
Genitourinary Cancer
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial
Eur Urol
Grimm MO, Smith M, Hussain M, Saad F, Fizazi K, Littleton N, Paracha N, Srinivasan S, Verholen F, Tombal B
doi: 10.1016/j.eururo.2025.05.037
RECOMMENDED
Head and Neck Cancer
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT
doi: 10.1016/j.lungcan.2025.108858
Genitourinary Cancer
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients
Eur Urol
Armstrong AJ, Petrylak DP, Shore ND, Szmulewitz RZ, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Croitoru R, Wu R, Kalac M, Tang Y, Stenzl A, Azad AA
doi: 10.1016/j.eururo.2025.12.021